Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs

Drug Resist Updat. 2023 Nov:71:101002. doi: 10.1016/j.drup.2023.101002. Epub 2023 Aug 22.

Abstract

Adenocarcinoma is a common type of malignant tumor, originating from glandular epithelial cells in various organs, such as pancreas, breast, lung, stomach, colon, rectus, and prostate. For patients who lose the opportunity for radical surgery, medication is available to provide potential clinical benefits. However, drug resistance is a big obstacle to obtain desired clinical prognosis. In this review, we provide a summary of treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs, including pancreatic cancer, gastric adenocarcinoma, colorectal adenocarcinoma, lung adenocarcinoma, and prostate cancer. Although the underlying molecular mechanisms involved in drug resistance of adenocarcinoma vary from one organ to the other, there are several targets that are universal for drug resistance in adenocarcinoma, and targeting these molecules could potentially reverse drug resistance in the treatment of adenocarcinomas.

Keywords: Adenocarcinoma; Chemotherapy; Resistance; Treatment; Tumor.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma* / drug therapy
  • Adenocarcinoma* / genetics
  • Colorectal Neoplasms*
  • Humans
  • Male
  • Pancreatic Neoplasms*
  • Prostatic Neoplasms*